ThioMatrix is specialised on the development of non-invasive drug delivery systems utilizing its core technologies: the Thiomer Technology and SEDDS Technology. Due to the great potential of these technologies the efficacy of non-invasively delivered:

• therapeutic peptides
  
  
• peptidomimetics
  
  
• nucleic acids such as oligonucleotides, plasmid DNA and siRNA
  
  
• class III drugs according to the biopharmaceutical classification system (BCS)
  
  
• drugs being substrate of efflux pumps such as anticancer drugs
  
  

can be tremendously improved. A wide network of partnerships and collaborations with hospitals, veterinary institutions, CROs and universities has been established to conduct preclinical through to clinical development of our delivery products. This network coupled to our technologies and expertise gives us the edge to reduce the time to market to develop the optimal delivery systems for your therapeutic candidates. To learn more about our drug delivery technologies, please visit the technology section where you will also find the results of various in vivo studies demonstrating the advantages of our novel drug delivery products.